Gates Foundation Backing Phase III Clinical Trial Of New TB Drug Regimen
News outlets report on the announcement of a Phase III clinical trial for a drug regimen that has the potential to fight drug-resistant tuberculosis.
The Guardian: New and better treatments for drug-resistant tuberculosis on the horizon
“A new trial of a novel drug combination that could dramatically shorten treatment for tuberculosis, including some of the drug-resistant strains, will start within the year — as long as enough money can be raised…” (Boseley, 4/23).
Reuters: Gates-backed TB drug to enter late-stage testing
“The first experimental drug that fights both conventional and drug-resistant forms of tuberculosis is advancing to late-stage clinical testing, researchers said on Wednesday, raising hope for a new way to stem the growing threat of drug-resistant TB…” (Steenhuysen, 4/23).
Wall Street Journal: Gates Foundation to Fund New Tuberculosis Drug Trial
“The Bill & Melinda Gates Foundation said Wednesday it would help fund a clinical trial of a promising drug regimen that, if effective, would offer a powerful new tool to fight drug-resistant tuberculosis…” (McKay, 4/23).
TB Alliance: New Tuberculosis Drug Regimen Will Move to Landmark Phase III Clinical Trial
“Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multidrug-resistant tuberculosis (TB) to a global Phase III clinical trial…” (4/23).